{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:11:42Z","timestamp":1788635502190,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.pnpbp.2017.03.009","type":"journal-article","created":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T17:48:08Z","timestamp":1490032088000},"page":"134-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The central mechanism of risperidone-induced hyperprolactinemia"],"prefix":"10.1016","volume":"76","author":[{"given":"Wei-Wei","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Chuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4239-2028","authenticated-orcid":false,"given":"Shu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 7","key":"10.1016\/j.pnpbp.2017.03.009_bb0005","first-page":"22","article-title":"Antipsychotic-induced weight gain: a review of the literature","volume":"62","author":"Allison","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0010","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0015","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin (PRL) inhibitor","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/2045125312442080","article-title":"Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment","volume":"2","author":"Bishop","year":"2012","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0269881112442016","article-title":"Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis","volume":"26","author":"Cookson","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0030","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/00004714-200210000-00024","article-title":"Re: Prolactin levels and adverse events in patients treated with risperidone","volume":"22","author":"Denisov","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0035","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0896-6273(00)80656-X","article-title":"Leptin activates hypothalamic CART neurons projecting to the spinal cord","volume":"21","author":"Elias","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269216307087148","article-title":"Prolactin and dopamine: what is the connection? A review article","volume":"22","author":"Fitzgerald","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0045","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: structure, function, and regulation of secretion","volume":"80","author":"Freeman","year":"2000","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0050","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1523\/JNEUROSCI.4441-06.2007","article-title":"White matter plasticity and enhanced remyelination in the maternal CNS","volume":"27","author":"Gregg","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0055","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/10401230209147453","article-title":"The effects of atypical antipsychotics on serum prolactin levels","volume":"14","author":"Hamner","year":"2002","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3758\/s13415-014-0261-3","article-title":"Antipsychotic dose modulates behavioral and neural responses to feedback during reinforcement learning in schizophrenia","volume":"14","author":"Insel","year":"2014","journal-title":"Cogn. Affect. Behav. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0070","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0075","doi-asserted-by":"crossref","first-page":"12742","DOI":"10.1073\/pnas.0404085101","article-title":"Y1 receptors regulate aggressive behavior by modulating serotonin pathways","volume":"101","author":"Karl","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0080","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3389\/fphys.2014.00480","article-title":"Hormonal regulation of the hypothalamic melanocortin system","volume":"5","author":"Kim","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","article-title":"Prolactin levels and adverse events in patients treated with risperidone","volume":"19","author":"Kleinberg","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0090","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.psyneuen.2008.08.015","article-title":"Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia","volume":"34","author":"Konarzewska","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2015.03.004","article-title":"Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: the role of histaminergic and NPY pathways","volume":"95-96","author":"Lian","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008488","article-title":"Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice","volume":"4","author":"Lin","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.tem.2015.01.003","article-title":"Regulation of energy homeostasis by the NPY system","volume":"26","author":"Loh","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0110","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.184.6.503","article-title":"Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia","volume":"184","author":"Meaney","year":"2004","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0115","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/0269881109348162","article-title":"Lactational exposure to atypical antipsychotic drugs disrupts the pituitary-testicular axis in mice neonates during post-natal development","volume":"24","author":"Mishra","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0120","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","article-title":"Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment","volume":"65","author":"Montgomery","year":"2004","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0125","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/070674371506001005","article-title":"Increased risk of obesity and metabolic dysregulation following 12 months of second-generation antipsychotic treatment in children: a prospective cohort study","volume":"60","author":"Ronsley","year":"2015","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0130","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.2337\/diabetes.51.12.3420","article-title":"Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob\/ob mice","volume":"51","author":"Sainsbury","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0135","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.beem.2014.04.003","article-title":"Hypothalamic control of bone metabolism","volume":"28","author":"Sharan","year":"2014","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0140","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cmet.2013.01.006","article-title":"Arcuate NPY controls sympathetic output and BAT function via a relay of tyrosine hydroxylase neurons in the PVN","volume":"17","author":"Shi","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0145","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1113\/jphysiol.2007.145896","article-title":"No stress please! Mechanisms of stress hyporesponsiveness of the maternal brain","volume":"586","author":"Slattery","year":"2008","journal-title":"J. Physiol."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0150","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fnbeh.2013.00140","article-title":"Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia","volume":"7","author":"Sumiyoshi","year":"2013","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0155","first-page":"929","article-title":"Pharmacological causes of hyperprolactinemia","volume":"3","author":"Torre","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0160","first-page":"183","article-title":"Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study","volume":"29","author":"Wang","year":"2014","journal-title":"Humanist. Psychol."},{"key":"10.1016\/j.pnpbp.2017.03.009_bb0165","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4088\/JCP.v60n0602","article-title":"Novel antipsychotics: comparison of weight gain liabilities","volume":"60","author":"Wirshing","year":"1999","journal-title":"The Journal of Clinical Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584616302512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584616302512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T04:12:30Z","timestamp":1719115950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584616302512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":33,"alternative-id":["S0278584616302512"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.03.009","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The central mechanism of risperidone-induced hyperprolactinemia","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}